Johnson & Johnson
As of Oct 22, 2026, Johnson & Johnson is in Stage 2, the uptrend phase, now in week 16 (since Jul 2, 2026). It closed at $267.61, 3.9% below its 52-week high and above its 200-day average, which is rising.
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 9 in Drug Manufacturers - General · #1 of 272 in Health Care
Is JNJ early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
JNJ among Drug Manufacturers - General7th of 21 by relative strength
All 21 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | MRK | Stage 2 · wk 16 | 92 | −0.6% |
| 2 | BIIB | Stage 2 · wk 21 | 92 | +11.6% |
| 3 | LLY | Stage 2 · wk 1 | 90 | +13.5% |
| 4 | AMGN | Stage 2 · wk 16 | 87 | +10.1% |
| 5 | OGN | Stage 2 · wk 23 | 87 | +0.1% |
| 6 | BMY | Stage 3 · wk 1 | 85 | +4.1% |
| 7 | JNJ | Stage 2 · wk 16 | 83 | −0.6% |
| 8 | PFE | Stage 2 · wk 8 | 77 | +7.9% |
Johnson & Johnson: quick answers
What stage is Johnson & Johnson in?
As of Oct 22, 2026, Johnson & Johnson (JNJ) is in Stage 2, the uptrend phase. It entered Stage 2 on Jul 2, 2026 and is in week 16. What the four stages mean
Is Johnson & Johnson in an uptrend?
Yes. Johnson & Johnson is in a Stage 2 uptrend. It trades 9.9% above its 200-day average, which is rising.
How far is Johnson & Johnson from its 52-week high?
Johnson & Johnson closed at $267.61 on Oct 22, 2026, 3.9% below its 52-week high of $278.43. Its 52-week low is $181.90.
How has Johnson & Johnson performed over the past year?
As of Oct 22, 2026, Johnson & Johnson is up 42.6% over the past year and up 31.1% so far in 2026.
Which sector and industry is Johnson & Johnson in?
Johnson & Johnson is in the Drug Manufacturers - General industry, part of the Health Care sector.
About this companyHealth Care· Drug Manufacturers - General
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.